Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSCPA.L Regulatory News (SCPA)

  • There is currently no data for SCPA

Trading Statement

12 Apr 2018 07:00

RNS Number : 6330K
Scapa Group PLC
12 April 2018
 

 

12 April 2018

 

Scapa Group plc ("Scapa" or "the Group")

 

Year-end trading update

 

Scapa Group plc (AIM: SCPA) is today providing an unaudited year end update for the twelve months ended 31 March 2018.  

 

The Group performed well and the good progress reported in the Interim Results has continued. Overall Group results are in line with the improved expectations outlined in the Group's October trading update.

Healthcare: Revenues grew 3.8% for the year, despite currency headwinds in H2. Sales growth in H2 was strong at 6.8% on a constant currency basis. Margins for the year are expected to be above 15% reflecting the investment in the integration of two technology transfers completed during the year.

Industrial: Industrial continues to deliver on its asset optimisation strategy. Industrial margin further improved driven by the benefit of Asian restructuring and more efficient cost to serve. The Markel acquisition is complete and site consolidations are underway.

Healthy cash flow in the period ensured the Group ended the year with net debt of ÂŁ3.8m, after the acquisition of Markel Industries for US$10.2m (ÂŁ7.6m) and BioMed Laboratories LLC for US$19m (ÂŁ13.6m).

Heejae Chae, CEO commented:

"This year we have delivered another set of strong results, and completed two acquisitions: Markel, our first Industrial acquisition, and BioMed, our first Healthcare acquisition outside adhesive technology. We also completed two technology transfers in Healthcare as we execute our growth strategy. I believe there is clear potential, in both Healthcare and Industrial, to further improve performance through organic growth, efficiency and acquisitions.

It is with great sadness that we announced yesterday a fatal accident at the Dunstable facility in the UK. I join with all of my colleagues and fellow directors in expressing our sincere condolences to the family and friends of the deceased."

Scapa expects to report its full year results on 22 May 2018.

This announcement contains inside information.

For further information:

Scapa Group plc Heejae Chae - Chief Executive Tel: 0161 301 7430

Graham Hardcastle - Finance Director

 

Numis Securities Limited Mark Lander, Richard Thomas Tel: 020 7260 1000

(Nominated Adviser/Joint Broker)

 

Berenberg Chris Bowman Tel: 020 3207 7800

(Joint Broker)

 

Weber Shandwick Financial PR Nick Oborne Tel: 0207 067 0000

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTFKDDPPBKDBQD
Date   Source Headline
2nd Jul 20184:33 pmRNSTotal Voting Rights
28th Jun 20184:12 pmRNSDirector/PDMR Shareholding
5th Jun 20184:00 pmRNSDirector/PDMR Shareholding
31st May 201810:31 amRNSTotal Voting Rights
30th May 201810:20 amRNSDirector/PDMR Shareholding
22nd May 20187:00 amRNSFinal Results
30th Apr 201810:30 amRNSTotal Voting Rights
12th Apr 20187:00 amRNSTrading Statement
11th Apr 20183:29 pmRNSIncident at Dunstable Site
29th Mar 201811:48 amRNSTotal Voting Rights
26th Mar 20187:00 amRNSAcquisition
28th Feb 20181:38 pmRNSTotal Voting Rights
7th Feb 20189:17 amRNSBlock listing Interim Review
31st Jan 20189:08 amRNSTotal Voting Rights
25th Jan 20182:14 pmRNSBlock listing Interim Review
8th Jan 201810:10 amRNSDirectorate Change
7th Dec 20173:52 pmRNSDirector/PDMR Shareholding
7th Dec 20173:49 pmRNSAdditional Listing
29th Nov 201711:15 amRNSDirector/PDMR Shareholding
28th Nov 20172:56 pmRNSDirector/PDMR Shareholding
28th Nov 20172:44 pmRNSDirector/PDMR Shareholding
23rd Nov 20179:36 amRNSDirector/PDMR Shareholding
21st Nov 20177:00 amRNSHalf-year Report
17th Nov 201710:22 amRNSAdditional Listing
11th Oct 20177:00 amRNSTrading Statement
4th Oct 20177:00 amRNSCapital Markets Day
26th Sep 201711:38 amRNSAdditional Listing
21st Sep 20174:21 pmRNSHolding(s) in Company
8th Sep 201711:31 amRNSDirector/PDMR Shareholding
4th Sep 20173:18 pmRNSDirector/PDMR Shareholding
4th Sep 201710:13 amRNSAdditional Listing
25th Aug 20177:00 amRNSDirector/PDMR Shareholding
17th Aug 20174:14 pmRNSDirector/PDMR Shareholding
11th Aug 20174:12 pmRNSDirector/PDMR Shareholding
9th Aug 20177:00 amRNSAcquisition
7th Aug 20171:56 pmRNSBlock listing Interim Review
25th Jul 201710:09 amRNSBlock listing Interim Review
19th Jul 20179:29 amRNSHolding(s) in Company
18th Jul 20177:00 amRNSAGM Statement
1st Jun 20171:59 pmRNSHolding(s) in Company
30th May 20172:09 pmRNSAdditional Listing
23rd May 20177:00 amRNSFinal Results
18th May 20173:47 pmRNSHolding(s) in Company
17th May 20173:36 pmRNSHolding(s) in Company
3rd May 201710:31 amRNSAdditional Listing
21st Apr 20179:41 amRNSHolding(s) in Company
19th Apr 20173:33 pmRNSAdditional Listing
13th Apr 20177:00 amRNSTrading Statement
27th Mar 20172:05 pmRNSDirector/PDMR Shareholding
23rd Mar 201711:46 amRNSAdditional Listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.